Shalby Ltd Share Price – NSE /  BSE

Healthcare, Small Cap

Net profit of Shalby reported to Rs 18.32 crore in the quarter ended March 2026 as against net loss of Rs 11.02 crore during the previous quarter ended March 2025. Sales rose 8.52% to Rs 287.45 crore in the quarter ended March 2026 as against Rs 264.89 crore during the previous quarter ended March 2025.

For the full year,net profit rose 501.13% to Rs 37.39 crore in the year ended March 2026 as against Rs 6.22 crore during the previous year ended March 2025. Sales rose 5.01% to Rs 1141.43 crore in the year ended March 2026 as against Rs 1086.96 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Shalby announced that the Company?fs step?]down subsidiary namely Ningen Lifecare (subsidiary of PK Healthcare) has been struck?]off from the Register of Companies by Ministry of Corporate Affairs w.e.f. 12 May 2026 as notified today on MCA website. Accordingly, Ningen Lifecare is now ceased to be subsidiary of PK Healthcare and consequently step?]down subsidiary of the Company.

Shalby will hold a meeting of the Board of Directors of the Company on 27 May 2026.

Shalby announced that Krishna Shalby Hospital, Ahmedabad, has inaugurated its Oncology Department along with advanced Radiotherapy facilities. The introduction of these oncology and radiotherapy services will ensure that patients have access to comprehensive cancer treatment under one roof.

With the launch of these advanced services, the hospital is now equipped to provide integrated cancer care. The department is supported by an experienced team of medical, radiation, and surgical oncologists, enabling patients to receive specialized diagnosis and treatment at a single location. Through advanced technology, expert medical teams, and a patient?]centric approach, we aim to ensure timely diagnosis and effective treatment for patients in and around Ahmedabad.

Powered by Capital Market - Live News